Chang Gung University

University of Colorado

Tsinghua University

S&t Biomed Co., Ltd.

Jau-Song Yu

Yu-Sun Chang

Ding Xue

Man Zhang

Qian Liang

Kai-Ping Chang

Jeng-Ting Chen

Hanzeng Li

Lingjun Zheng

Tseng-Fu Lu

Chao-Sung Lai

Yu Peng

I-Shun Wang

Yi-Ting Chen

Jinn-Shiun Chen

Po-Lung Yang

Yi-Ting Lin

Wen-Yu Chuang

Ting-Chun Yu

Jyh-Ping Chen

Chou Chien

Wei-Fan Chiang

Kuei-Tien Chen

Err-Cheng Chan

Lai-Chu See

The invention provides novel compositions and methods for the treatment of Radiation-Induced Bystander Effects (RIBE), resulting from radiation exposure. In one preferred embodiment the inventions includes novel therapeutic agents, including but not limited to quercetin and quercetin analogs, as well as E64, CA074, CA074Me, that interfere with the activity of Cathepsin B.

Compositions and methods for preventing and treating radiation-induced bystander effects caused by radiation or radiotherapy

Disclosed herein is a method of determining whether a subject has or is at risk of developing a cancer. The method comprises, obtaining a sample from the subject; determining the levels of at least two target polypeptides, which are selected from the group consisting of, ANXA2, HSPA5, KNG1 and MMP1; and assessing whether the subject has or is at risk of developing the cancer based on the levels of target polypeptides. The present method provides a potential means to diagnose and predict the occurrence of oral squamous cell carcinoma, and accordingly, the subject in need thereof could receive a suitable therapeutic regimen in time.

Method for cancer diagnosis and prognosis

Embodiments relate to serological markers for detecting the colorectal cancer and applications of the serological markers. A phospholipid scramblase1 (PLSCR1), a stomatin-like protein 2 (STOML2) or a transport protein Sec61&#x3b2; (SEC61&#x3b2;) increases expression in the blood at the earlier stage of the colorectal cancer. Detecting the expression of the PLSCR1, STOML2 or SEC61&#x3b2; protein or an induced autoantibody of each protein in a blood sample is used to diagnose the colorectal cancer. Moreover, the serological marker improves the detection efficiency and the sensitivity in detecting the colorectal cancer and is used to predict the prognosis. The serological markers are applied in preparing a detection device or inhibiting the growth of the colorectal cancer cells.

Serological markers for detecting colorectal cancer and their application for inhibiting colorectal cancer cells

The NHplasma treatment by remote plasma is firstly proposed to replace the covalent bonding process during surface modification procedure that for amine bond generation.

[object Object]

A method of detecting malignancy of nasopharyngeal carcinoma and a nasopharyngeal carcinoma malignancy biomarker are disclosed. Firstly, a specimen is obtained from a testee. Next, the specimen is tested for its MIP-3&#x3b1; expression level. Then, the MIP-3&#x3b1; expression level of the specimen is compared with that of a control. Finally, the malignancy of nasopharyngeal carcinoma is determined according to a relative MIP-3&#x3b1; expression level between the specimen and the control.

Method of detecting malignancy of nasopharyngeal carcinoma and a nasopharyngeal carcinoma malignancy biomarker

Growing community of inventors

Taoyuan, Taiwan

Jau-Song Yu